Phase 1 Clinical Trial of Elamipretide in Dry Age-Related Macular Degeneration and Noncentral Geographic Atrophy: ReCLAIM NCGA Study

PURPOSE: Assess the safety, tolerability, and feasibility of subcutaneous administration of the mitochondrial-targeted drug elamipretide in patients with dry age-related macular degeneration (AMD) and noncentral geographic atrophy (NCGA) and to perform exploratory analyses of change in visual functi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mettu, Priyatham S., Allingham, Michael J., Cousins, Scott W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560640/
https://www.ncbi.nlm.nih.gov/pubmed/36246181
http://dx.doi.org/10.1016/j.xops.2021.100086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560640/
https://www.ncbi.nlm.nih.gov/pubmed/36246181
http://dx.doi.org/10.1016/j.xops.2021.100086

Ejemplares similares